BioCentury | Nov 4, 2013
Finance

Calithera metabolizes

...Cost of sales increased 17% to $17.2M, which included $1M in cost of authorized generic tizanidine...
BioCentury | Mar 25, 2013
Clinical News

Sativex regulatory update

According to GW Pharmaceuticals, European marketing partner Almirall S.A. (Madrid:ALM, Barcelona, Spain) said the price in Germany for Sativex to treat spasticity due to multiple sclerosis is "unacceptable." An independent arbitration board determined the price...
BioCentury | Mar 20, 2013
Company News

GW says partner finds German Sativex price 'unacceptable'

According to GW Pharmaceuticals plc (LSE:GWP), European marketing partner Almirall S.A. (Madrid:ALM) said the price in Germany for Sativex to treat spasticity due to multiple sclerosis (MS) is "unacceptable." An independent arbitration board determined the...
BioCentury | Aug 27, 2012
Strategy

Another cut at Elan

...AD vaccine in Phase II testing. Soon after, the company's biggest product, spasticity drug Zanaflex tizanidine...
BioCentury | Jun 25, 2012
Clinical News

Sativex regulatory update

Germany's Federal Joint Committee (G-BA) said Sativex from GW Pharmaceuticals provides a "marginal" degree of additional benefit over optimized standard therapy to treat spasticity in multiple sclerosis (MS) patients. In April, the Institute for Quality...
BioCentury | Jun 22, 2012
Company News

G-BA says Sativex offers 'marginal' additional benefit

Germany's Federal Joint Committee (G-BA) said Sativex from GW Pharmaceuticals plc (LSE:GWP) provides a "marginal" degree of additional benefit over optimized standard therapy to treat spasticity in multiple sclerosis (MS) patients. In April, the Institute...
BioCentury | Apr 9, 2012
Clinical News

Sativex regulatory update

The German Institute for Quality and Efficiency in Health Care (IQWiG) issued a preliminary benefit assessment that assigned Sativex from GW Pharmaceuticals a rating of "no additional benefit" for the indication of treating spasticity in...
BioCentury | Apr 3, 2012
Company News

IQWiG assigns Sativex 'no additional benefit' rating

The German Institute for Quality and Efficiency in Health Care (IQWiG) issued a preliminary benefit assessment that assigned Sativex from GW Pharmaceuticals plc (LSE:GWP) a rating of "no additional benefit" for the indication of treating...
BioCentury | Feb 13, 2012
Company News

Acorda, Watson sales and marketing update

...Watson Pharma Inc. subsidiary launched in the U.S. an authorized generic of spasticity drug Zanaflex tizanidine...
...drug from Elan Corp. plc (NYSE:ELN, Dublin, Ireland) under a 2004 deal. Net revenue of Zanaflex...
BioCentury | Nov 7, 2011
Finance

Clovis closes in

...Acorda also reported $15.4M in charges related to a September Court decision finding its Zanaflex tizanidine...
Items per page:
1 - 10 of 98